Diseases of the circulatory system
Conditions
Interventions
The intervention group received pharmaceutical follow-up (n=21). This was carried out by the study pharmacist and researcher, monthly, during home visits. After the initial assessment, a care plan was
counseling the patient/caregiver about specific health conditions and counseling the patient/caregiver about general health conditions were provided to all patients. Other interventions performed acco
Advice on self-monitoring
Advice on access to medications
Advice on storage of medicines
Drug suspension
Drug replacement
Change of drug dose
Laboratory monitoring recommendation
Referral to the doctor
referral to the nurse
to the physiotherapist
to the nutritionist
the social support service and the structured education program
Provision of material - list or medication dosage schedule
Provision of material - pictorial labels/instructions
Provision of material - diary for self-monitoring
Provision of material - medication organizer or device to aid adherence.
The follow-up of the control group (n=17) was carried out by researchers, who had been previously trained, monthly, at their ho
Sponsors
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: patients using warfarin for chronic diseases, residing in the urban area of ??the city of Ijuí / RS, having consulted in a Health Unit in the city.
Exclusion criteria
Exclusion criteria: patients residing in the rural area of ??the municipality (due to the logistics for monitoring), those who stopped using warfarin before the first interview, and who did not agree to sign the informed consent form and participate in the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimizing the incidence of bleeding, assessed by direct questioning the interviewee at each visit with a decrease of at least 5% in the number of bleeding patients.;Improvement of the length of stay in the INR therapeutic range assessed by the difference between the two consecutive INR values and the target limit value, after dividing these values, the percentage of days within the therapeutic interval is obtained with a 10% increase in patients with time of permanence in the therapeutic range. | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimization of thrombotic events and other adverse events assessed by direct questioning to the interviewee at each visit with a 10% decrease in thrombotic events and other adverse events.;Reduction in hospital admissions assessed by direct questioning the interviewee at each visit with a 50% decrease in patients who will not be admitted during the study period.;Reduction of drug interactions identified through Micromedex® Solutions Drug Interactions including all drugs (prescribed and that each patient used in the first and last month of follow-up and individually checked each, with a minimum reduction of 10% in the number of interactions that the patient was susceptible.;Reduction in the average number of medications assessed by direct questioning the interviewee at each visit with a 10% decrease in patients who decreased the number of medications. | — |
Countries
Brazil
Contacts
Public ContactEliane Winkelmann
Universidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI
Outcome results
None listed